IL318816A - Mta-cooperative prmt5 inhibitors for use in the treatment of cancer - Google Patents

Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Info

Publication number
IL318816A
IL318816A IL318816A IL31881625A IL318816A IL 318816 A IL318816 A IL 318816A IL 318816 A IL318816 A IL 318816A IL 31881625 A IL31881625 A IL 31881625A IL 318816 A IL318816 A IL 318816A
Authority
IL
Israel
Prior art keywords
mta
cooperative
cancer
treatment
prmt5 inhibitors
Prior art date
Application number
IL318816A
Other languages
Hebrew (he)
Inventor
James Thomas Lynch
Ho Man Chan
Original Assignee
Astrazeneca Ab
James Thomas Lynch
Ho Man Chan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, James Thomas Lynch, Ho Man Chan filed Critical Astrazeneca Ab
Publication of IL318816A publication Critical patent/IL318816A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02028—S-Methyl-5'-thioadenosine phosphorylase (2.4.2.28)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91142—Pentosyltransferases (2.4.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL318816A 2022-08-15 2023-08-14 Mta-cooperative prmt5 inhibitors for use in the treatment of cancer IL318816A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263397996P 2022-08-15 2022-08-15
PCT/EP2023/072364 WO2024038004A1 (en) 2022-08-15 2023-08-14 Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
IL318816A true IL318816A (en) 2025-04-01

Family

ID=87748037

Family Applications (1)

Application Number Title Priority Date Filing Date
IL318816A IL318816A (en) 2022-08-15 2023-08-14 Mta-cooperative prmt5 inhibitors for use in the treatment of cancer

Country Status (11)

Country Link
US (1) US20260048040A1 (en)
EP (1) EP4572760A1 (en)
JP (1) JP2025528186A (en)
KR (1) KR20250048049A (en)
CN (1) CN119730853A (en)
AU (1) AU2023327684A1 (en)
CA (1) CA3263923A1 (en)
IL (1) IL318816A (en)
MX (1) MX2025001965A (en)
TW (1) TW202423435A (en)
WO (1) WO2024038004A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (en) 2023-04-21 2026-01-16 Gilead Sciences Inc PRMT5 INHIBITORS AND THEIR USES
WO2026114356A1 (en) * 2024-11-29 2026-06-04 普罗思特(南京)生物科技有限公司 Nitrogen-containing heterocyclic compounds and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3160958T3 (en) 2014-06-25 2021-04-12 Glaxosmithkline Ip Dev Ltd CRYSTALLINAL SALTS OF (S) -6 - ((1-ACETYLPIPERIDIN-4-YL) AMINO) -N- (3- (3,4-DIHYDROISOQUINOLIN-2 (1H) -YL) -2-HYDROXYPROPYL) PYRIMIDIN-4- CARBOXAMID
CN120208880A (en) * 2019-09-12 2025-06-27 米拉蒂医疗股份有限公司 MTA-synergistic PRMT5 inhibitor
US12403137B2 (en) 2019-10-28 2025-09-02 Tango Therapeutics, Inc. Compounds and methods of use
MX2022010011A (en) 2020-02-12 2022-10-18 Amgen Inc Novel prmt5 inhibitors.
CN116568677B (en) 2020-07-31 2026-07-28 探戈医药股份有限公司 Piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers
EP4251624B1 (en) 2020-11-24 2025-10-29 Amgen Inc. Tricyclic carboxamide derivatives as prmt5 inhibitors
LT4263545T (en) 2020-12-16 2026-07-27 Amgen Inc. Prmt5 inhibitors
RU2757957C1 (en) 2020-12-30 2021-10-25 Александр Григорьевич ВИЛЛЕР Robotic system and method for endovascular surgery
CN117062816A (en) 2021-02-04 2023-11-14 美国安进公司 Tricyclic-amide-bicyclic PRMT5 inhibitors
EP4304720A1 (en) 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
US20240368153A1 (en) 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
EP4402143A1 (en) 2021-09-13 2024-07-24 Astrazeneca AB Spirocyclic compounds
KR20240157631A (en) 2021-11-05 2024-11-01 미라티 테라퓨틱스, 인크. 2-Aminoimidazole derivatives as PRMT5 inhibitors
EP4442680A4 (en) 2021-11-30 2026-05-06 Abbisko Therapeutics Co Ltd Pyrazole derivative and method of manufacture thereof and use thereof in medicine
CN116462677A (en) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 A kind of multi-fused ring PRMT5 inhibitor and its preparation method and application
CN116462676A (en) 2022-01-20 2023-07-21 上海和誉生物医药科技有限公司 A kind of multi-fused ring PRMT5 inhibitor and its preparation method and application
CN116178347B (en) 2022-06-29 2025-07-04 苏州浦合医药科技有限公司 PRMT5-MTA inhibitors

Also Published As

Publication number Publication date
AU2023327684A1 (en) 2025-03-20
US20260048040A1 (en) 2026-02-19
EP4572760A1 (en) 2025-06-25
KR20250048049A (en) 2025-04-07
CA3263923A1 (en) 2024-02-22
JP2025528186A (en) 2025-08-26
MX2025001965A (en) 2025-04-02
WO2024038004A1 (en) 2024-02-22
TW202423435A (en) 2024-06-16
CN119730853A (en) 2025-03-28

Similar Documents

Publication Publication Date Title
IL308195A (en) Ras inhibitors for the treatment of cancer
IL288395A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
PT4181920T (en) Kat6 inhibitor methods and combinations for cancer treatment
IL315996A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
IL277665A (en) Heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284324A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL284326A (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
IL316829A (en) Menin-mll inhibitors for the treatment of cancer
IL321393A (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
IL321326A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
SMT202500434T1 (en) Sotorasib for use in the treatment of cancer
IL312650A (en) Cdk4 inhibitor for the treatment of cancer
HUE070568T2 (en) Heterocyclic compounds for use in the treatment of cancer
IL319269A (en) Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer
IL276668A (en) Thioredoxin reductase inhibitors for use in the treatment of cancer
CA3263923A1 (en) Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
IL288665A (en) Methods of treating cancer using prmt5 inhibitors
IL292143A (en) Alkylesters of alpha-methyl-dl-tyrosine for use in treating cancer
IL305780A (en) Methods for the treatment of cancer
IL327337A (en) Cancer treatments using mta-cooperative prmt5 inhibitors
HK40128085A (en) Mta-cooperative prmt5 inhibitors for use in the treatment of cancer
IL319193A (en) Combination therapies using prmt5 inhibitors and bcl-2 family inhibitors for the treatment of cancer
IL311668A (en) Cyp11a1 inhibitor for use in the treatment of prostate cancer
CA3283117A1 (en) Prmt5 inhibitor for use in cancer therapy
CA3273124A1 (en) Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer